Early-stage investor Syncona readjusts priorities due to bleak biotech market
The desolate biotech financing environment is starting to take a toll on investment funds, with the UK life sciences firm Syncona announcing it is realigning its priorities. Syncona will look for ways...
View ArticleUK's NICE says Alzheimer's drugs aren't worth national coverage
Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla should not be covered under the UK's national health insurance because the Alzheimer's drugs' benefits don't outweigh their high cost, the country's...
View ArticlePharma companies are weighing how a drug’s IP location could impact tariffs
Over the past few months, several biopharma companies like GSK, Merck, Alnylam and BioMarin have said they are monitoring how the location of their drugs’ intellectual property could be relevant to...
View ArticleFDA to biotech CEOs: US is lagging behind on early-stage trials
Top FDA officials sided with biotech CEOs this week on the need to speed up drug reviews to stay competitive with China and other countries, in the latest agency "listening" session with industry....
View ArticleCHMP recommends five new drugs, reconsiders Eli Lilly’s Kisunla
The European Medicines Agency’s human medicines committee (CHMP) recommended the authorization of five new medicines this week and announced that it has begun its reexamination of Eli Lilly’s...
View Article#ADA25: Vertex's diabetes cell therapy allows 10 patients to come off insulin
Vertex Pharmaceuticals’ cell therapy for type 1 diabetes allowed 10 of 12 patients (83%) to stop taking insulin a year after they were infused, according to results presented Friday. The data came from...
View ArticleFDA unveils new pilot program; Sage finds a buyer; Eli Lilly to acquire...
Welcome back to another edition of Endpoints Weekly, and happy start to the summer! The North Pole reached its maximum tilt toward the sun at 2:42 a.m. UTC this morning (10:42 p.m. Friday night on ...
View ArticleA puzzling update from Novo Nordisk and new data from Roche at #ADA25
The annual meeting of the American Diabetes Association is underway in Chicago. The confab has already yielded a major update from Vertex Pharmaceuticals and more exciting data are on the way. But ...
View ArticleCompass reports Phase 3 depression data for psilocybin drug
Compass Pathways said Monday its psilocybin drug has cleared the first of two late-stage tests in a challenging form of depression as it advances toward the potential of becoming the first classical...
View ArticleIllumina to buy SomaLogic for $350M upfront, pushing further into proteomics
Illumina has agreed to pay $350 million upfront for SomaLogic, the companies announced on Monday, in a deal that underscores the DNA giant's strategy of offering a broader look at biology. SomaLogic...
View Article#ADA25: Lilly’s bimagrumab boosts weight and fat loss when added to Novo's...
Eli Lilly’s muscle-boosting drug allowed obese patients who are taking Novo Nordisk’s Wegovy to retain almost all of their lean tissue, according to data presented Monday. The data are from a Phase 2b...
View ArticleTop drug regulator to depart FDA in July
The top drug regulator at the FDA is retiring, according to an email reviewed by Endpoints News and confirmed by several individuals within the agency. Jacqueline Corrigan-Curay, who’s been at the...
View ArticleCidara's preventive influenza biologic is effective in Phase 2b trial
Cidara Therapeutics’ long-acting antiviral biologic effectively prevented seasonal flu infections in a mid-stage trial, the biotech said Monday. Its shares {$CDTX} were up 95% in early trade on the...
View ArticleFormation Bio’s up to €545M licensing deal with Sanofi; Otsuka, Harbour...
Plus, news about Incyte, Carisma Therapeutics, Idorsia, Leap Therapeutics, Enterome, Merck, Forte Biosciences, Enzon and Viskase: Formation Bio licenses JAK/SYK inhibitor to Sanofi: The startup said...
View ArticleNovo Nordisk ends partnership with Hims over compounded drugs
Novo Nordisk has ended its unlikely partnership with Hims & Hers after less than two months. In late April, the pharma giant started allowing Hims, along with other telehealth companies, direct...
View ArticleExelixis' positive Phase 3 colorectal cancer data boost stock
Shares {$EXEL} of Exelixis jumped after the company reported positive Phase 3 data from one of its cancer studies. Exelixis said Monday that a combination of its oral TKI inhibitor zanzalintinib ...
View ArticleSupreme Court asks DOJ to weigh in on Hikma ‘skinny label’ fight
The US Supreme Court on Monday invited the US solicitor general to comment on a generic drug label case that Hikma Pharmaceuticals says could “effectively vitiate” a common practice for bringing...
View ArticleRoche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3
Roche is moving its next-generation hemophilia A treatment into Phase 3 testing next year after seeing the early-stage data. The pharma disclosed Monday that part of the Phase 3 program will ...
View ArticleFDA approves AstraZeneca, Daiichi Sankyo's Datroway in EGFR-mutated lung cancer
The FDA on Monday approved AstraZeneca and Daiichi Sankyo’s TROP2-targeting drug Datroway in a new lung cancer indication, broadening the amount of patients for what the company hopes is their next big...
View Article#ADA25: Amgen plans more gradual MariTide dosing in Phase 3
Amgen intends to dose its long-acting obesity shot MariTide at a lower level in its Phase 3 than it did in Phase 2, after the drug’s side effects proved unmanageable in mid-stage research. The adverse ...
View Article